Comparing the clinical utility of pharmacogenomic genotyping and next generation sequencing in a military health system adult medicine clinic
Preemptive multi-gene NGS detected more clinically actionable PGx results than targeted <i>CYP2C19/CYP2D6</i> genotyping. Effective PGx screening in the MHS may decrease preventable adverse effects and improve military readiness.
Authors
- Mark C. Haigney (ORCID: https://orcid.org/0000-0001-6449-4386)
- Keiko Fox (ORCID: https://orcid.org/0000-0001-6919-4569)
- Clesson Turner (ORCID: https://orcid.org/0000-0001-7625-8022)
- Mauricio De Castro
- Lucas Poon
- Ann M. Moyer (ORCID: https://orcid.org/0000-0003-2590-7218)
- Steven E. Scherer (ORCID: https://orcid.org/0000-0002-3719-3673)
- John L. Black (ORCID: https://orcid.org/0000-0001-6726-7293)
- David Saunders (ORCID: https://orcid.org/0000-0003-0946-1164)
- Sanjay Kalra (ORCID: https://orcid.org/0000-0003-1308-121X)
- Thomas Arnold (ORCID: https://orcid.org/0009-0003-9665-4518)
- Lydia D. Hellwig (ORCID: https://orcid.org/0000-0003-0592-3552)
- Andrew Heroy (ORCID: https://orcid.org/0009-0004-6582-7604)
- Joya Libbus
- Austin Pagani
- Nate Ehat
Institutions
- Henry M. Jackson Foundation (US)
- National Institutes of Health (US)
- Mayo Clinic (US)
- Uniformed Services University of the Health Sciences (US)
- Baylor College of Medicine (US)
- Defense Health Agency (US)
- Walter Reed National Military Medical Center (US)
- WinnMed (US)
- Jackson Memorial Hospital (US)
- University of Mississippi Medical Center (US)
- Keesler Medical Center (US)
Publication Details
- Journal
- Pharmacogenomics
- Published
- 2024-12-11
- DOI
- https://doi.org/10.1080/14622416.2025.2466413
- Citations
- 2
- Primary Topic
- Pharmacogenetics and Drug Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.93
Funders
- Defense Health Agency